Skip to content

CorMedix CRMD Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Merck & Co. logo
Merck & Co.MRK
ITG
Integer HoldingsITGR
IAR
Integra LifeSciencesIART
Emergent Biosolutions logo
Emergent BiosolutionsEBS
Abbott logo
AbbottABT
ICU Medical logo
ICU MedicalICUI

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's common stock, shares authorized (in shares)?
CorMedix (CRMD) reported common stock, shares authorized (in shares) of $160M in Q1 2026.
How has CorMedix's common stock, shares authorized (in shares) changed year-over-year?
CorMedix's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $160M to $160M.
What is the long-term trend for CorMedix's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), CorMedix's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $160M to $160M.